<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039103</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0303-CL-204</org_study_id>
    <secondary_id>2009-013884-21</secondary_id>
    <nct_id>NCT01039103</nct_id>
  </id_info>
  <brief_title>Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)</brief_title>
  <official_title>A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with
      Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily
      infusions of SoluMedrol. Main objective is to assess the occurrence of new
      gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 8.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 4.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by changes in MSIS-29</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response measured by changes in MSFC</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of free prednisolone and prednisolone phosphate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acute Exacerbation of Remitting Relapsing Multiple Sclerosis</condition>
  <condition>Clinically Isolated Syndrome</condition>
  <arm_group>
    <arm_group_label>Nanocort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solu-Medrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-liposomal prednisolone sodium phosphate</intervention_name>
    <description>PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1</description>
    <arm_group_label>Nanocort</arm_group_label>
    <other_name>Nanocort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3</description>
    <arm_group_label>Solu-Medrol</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION criteria

          -  Diagnosis of RRMS (per McDonald criteria, 2005) with dissemination in time and space
             OR a diagnosis of CIS confirmed by MRI. Patients with CIS who only have optic neuritis
             will be excluded from this study

          -  A maximum Expanded Disability Status Scale (EDSS) score of ≤ 6

          -  New neurological symptoms or exacerbation of prior neurological symptoms of over 24
             hours duration but &lt;7 days duration, verified by neurological examination

        EXCLUSION criteria:

          -  Primary progressive MS.

          -  Secondary progressive MS without superimposed relapses.

          -  Received systemic corticosteroids within 4 weeks of screening for treatment of MS or
             other conditions.

          -  any contraindication for treatment with (systemic) corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Beetens, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement Neurologie AZ St Jan AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationaal MS Centrum</name>
      <address>
        <city>Melsbroek</city>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revalidatie &amp; MS-centrum Overpelt</name>
      <address>
        <city>Overpelt</city>
        <zip>B-3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hohe Warte, Neurologische Klinik</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef Hospital der Ruhr</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der technischen Universitaet Muenchen, Neurologische Klinik und Poliklinik</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnomed-Clinical Research Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-594</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PEG-liposomal prednisolone sodium phosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

